Stock Markets February 10, 2026

Gerresheimer Delays 2025 Results as Accounting Probe Expands; Puts U.S. Packaging Unit Centor up for Sale

German medical-equipment maker engages a second auditor, revises profit and revenue guidance after regulator review of revenue recognition

By Maya Rios
Gerresheimer Delays 2025 Results as Accounting Probe Expands; Puts U.S. Packaging Unit Centor up for Sale

Gerresheimer has postponed publication of its 2025 results while it addresses a regulatory review into its revenue recognition and accounting practices. The company has begun the divestment process for its U.S.-based packaging systems business, Centor, and engaged an additional auditing firm to examine 2024 and 2025 accounting. It revised its 2025 revenue and EBITDA margin guidance downward and warned adjusted EPS may fall sharply or become negative.

Key Points

  • Gerresheimer postponed publication of its 2025 results while addressing a regulatory review and internal examinations of revenue recognition and accounting practices.
  • The company has launched a sale process for Centor, its U.S.-based packaging systems business, and engaged a second auditing firm to review 2024 and 2025 accounting.
  • Gerresheimer cut its 2025 guidance: revenue decline expected toward the higher end of minus 4% to minus 2%; adjusted EBITDA margin reduced to 16.5%–17.5% from 18.5%–19.0%; adjusted EPS forecast to fall in the high-double-digit percentage range and may become negative.

Gerresheimer said on Tuesday that it has pushed back the release of its 2025 results amid an internal and external review of its accounting and revenue recognition procedures, and that it has initiated a sale process for its U.S.-based packaging systems business, Centor.

The company's move follows a September announcement from Germany's financial regulator, BaFin, which said it would review Gerresheimer's financial statements as of November 30, 2024, citing concerns that the company may have recognised revenue too early on certain customer contracts.

In addition to the regulatory review, Gerresheimer said it has hired a second auditing firm to carry out an examination of revenue recognition and accounting practices covering 2024 and 2025. The company indicated the audit findings will have consequences for its 2025 outlook.

Gerresheimer stated that, based on findings to date, its newly initiated investigations point to instances in which individual employees violated internal guidelines and International Financial Reporting Standards requirements. The company said the ongoing work by auditors and internal investigations will determine the full impact.

As a result of these developments, the company now expects the reduction in 2025 revenues to sit at the higher end of its prior guidance range of minus 4% to minus 2%, or slightly better. It also trimmed its forecast for adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) margin to a range of 16.5% to 17.5%, down from an earlier range of 18.5% to 19.0%.

Gerresheimer warned that adjusted earnings per share for 2025 are now expected to decline in the high-double-digit percentage range and could turn negative, contingent on the outcomes of the investigations and audits.

The company did not provide additional detail on the timing of the Centor sale or on the precise timetable for the completion of the second auditor's review, noting only that the results of these processes will feed into its updated outlook for 2025.


Clear summary

Gerresheimer has delayed its 2025 results amid a BaFin review and internal investigations into revenue recognition. The firm engaged a second auditor to examine 2024 and 2025 accounting, initiated a sale of its Centor packaging business, and revised down its 2025 revenue and EBITDA margin guidance while warning of a steep drop in adjusted EPS.

Risks

  • Ongoing regulatory review and auditor investigations could produce findings that further weaken the company's 2025 financial outlook - impacts financial and capital markets related to the company.
  • Indications that individual employees violated internal guidelines and IFRS create operational, compliance and reputational risks for Gerresheimer - affects corporate governance and investor confidence.
  • The initiation of a sale process for Centor introduces transactional uncertainty until the divestment is completed - relevant to the medical packaging and manufacturing sectors.

More from Stock Markets

S&P 500 Shows Signs of Tightening Range; Strategist Sees Potential for a Big Move Feb 22, 2026 Supreme Court to Clarify Reach of Helms-Burton Act in Multi-Billion Dollar Cuba Claims Feb 22, 2026 Switzerland Pulling Ahead in Early Economic Gains from AI Feb 22, 2026 Nvidia Results and Software Earnings to Test AI-Driven Market Sentiment Feb 22, 2026 Analysts Shift AI Bets: Nvidia, Amazon, Dell, Analog Devices, Shopify See Upgrades and Bullish Casework Feb 22, 2026